Reza Samanipour, Sara Tabatabaee, Mahsa Delyanee, Amirhossein Tavakoli
{"title":"The promising approach of MSCs therapy for COVID-19 treatment.","authors":"Reza Samanipour, Sara Tabatabaee, Mahsa Delyanee, Amirhossein Tavakoli","doi":"10.1007/s10561-022-10060-2","DOIUrl":null,"url":null,"abstract":"<p><p>Several ongoing investigations have been founded on the development of an optimized therapeutic strategy for the COVID-19 virus as an undeniable acute challenge for human life. Cell-based therapy and particularly, mesenchymal stem cells (MSCs) therapy has obtained desired outcomes in decreasing the mortality rate of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), mainly owing to its immunoregulatory impact that prevents the overactivation of the immune system. Also, these cells with their multipotent nature, are capable of repairing the damaged tissue of the lung which leads to reducing the probability of acute respiratory distress syndrome (ARDS). Although this cell-based method is not quite cost-effective for developing countries, regarding its promising results in order to treat SARS-COV-2, more economical evaluation as well as clinical trials should be performed for improving this therapeutic approach. Here in this article, the functional mechanism of MSCs therapy for the treatment of COVID-19 and the clinical trials based on this method will be reviewed. Moreover, its economic efficiency will be discussed.</p>","PeriodicalId":9723,"journal":{"name":"Cell and Tissue Banking","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757632/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell and Tissue Banking","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s10561-022-10060-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 2
Abstract
Several ongoing investigations have been founded on the development of an optimized therapeutic strategy for the COVID-19 virus as an undeniable acute challenge for human life. Cell-based therapy and particularly, mesenchymal stem cells (MSCs) therapy has obtained desired outcomes in decreasing the mortality rate of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), mainly owing to its immunoregulatory impact that prevents the overactivation of the immune system. Also, these cells with their multipotent nature, are capable of repairing the damaged tissue of the lung which leads to reducing the probability of acute respiratory distress syndrome (ARDS). Although this cell-based method is not quite cost-effective for developing countries, regarding its promising results in order to treat SARS-COV-2, more economical evaluation as well as clinical trials should be performed for improving this therapeutic approach. Here in this article, the functional mechanism of MSCs therapy for the treatment of COVID-19 and the clinical trials based on this method will be reviewed. Moreover, its economic efficiency will be discussed.
期刊介绍:
Cell and Tissue Banking provides a forum for disseminating information to scientists and clinicians involved in the banking and transplantation of cells and tissues. Cell and Tissue Banking is an international, peer-reviewed journal that publishes original papers in the following areas:
basic research concerning general aspects of tissue banking such as quality assurance and control of banked cells/tissues, effects of preservation and sterilisation methods on cells/tissues, biotechnology, etc.; clinical applications of banked cells/tissues; standards of practice in procurement, processing, storage and distribution of cells/tissues; ethical issues; medico-legal issues.